Vertex Announces European Commission Approval for KALYDECO ® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for KALYDECO® (ivacaftor) granules to include the treatment of infants with cystic fibrosis (CF) ages 4 months and older and weighing at least 5 kg who have the R117H mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
“Our very first CFTR modulator, KALYDECO, was first approved eight years ago, for certain CF patients ages 6 years and older. With today’s approval, babies as young as 4 months are eligible and we believe early treatment is important in managing CF,” said Reshma Kewalramani, M.D., Chief Executive Officer and President, Vertex. “Today’s approval is a testament to our commitment to keep going until all people with CF have a treatment option.”
The label update is based on data from a cohort in the 24-week Phase 3 open-label safety study (ARRIVAL) consisting of six children with CF ages four months to less than six months who have eligible gating mutations.
KALYDECO® (ivacaftor) will be now available to additional eligible patients in Germany and will be available shortly in countries that have entered into innovative long-term reimbursement agreements with Vertex, including the UK, Denmark and the Republic of Ireland. In all other countries, Vertex will work closely with relevant authorities in Europe to secure access for eligible patients.
KALYDECO® (ivacaftor) is already approved in Europe for people with CF ages 6 months and older weighing at least 5 kg who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, R117H, S1251N, S1255P, S549N or S549R.
About Cystic Fibrosis
Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.
About KALYDECO® (ivacaftor)
Ivacaftor is the first medicine to treat the underlying cause of CF in people with specific mutations in the CFTR gene. Known as a CFTR potentiator, ivacaftor is an oral medicine designed to keep CFTR proteins at the cell surface open longer to improve the transport of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways.
For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.
Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Dr. Reshma Kewalramani in this press release, and statements regarding the eligible patient population in Europe, our expectations regarding the timing of access to KALYDECO for eligible patients four months of age and older across countries in Europe, and our plans to secure access to KALYDECO for additional eligible patients four months of age and older in Europe. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, risks related to commercializing KALYDECO in Europe, and other risks listed under Risk Factors in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Vertex Pharmaceuticals Incorporated
International: +44 20 3204 5275
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
O-RAN ALLIANCE Announces New Specifications and Demos, First Open Test and Integration Centers and Its June 29 Industry Summit24.6.2021 00:22:00 CEST | Press release
O-RAN ALLIANCE welcomes stc as its new operator member, building up the world-wide community of 29 mobile network operators committed to deployment of open and intelligent Radio Access Networks (RAN). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005961/en/ O-RAN Logical Architecture (Graphic: Business Wire) 33 New or Updated O-RAN Specifications Released since March 2021 On June 17, 2021, the O-RAN ALLIANCE published another 33 specification documents, including 11 new titles. Among others these new specifications include: Management interface, timing and synchronization for Transport The baseline for Non-Real-Time Radio Intelligent Controller (Non-RT RIC) and Near-Real-Time RIC Architecture and interfaces (E2, A1, F1/X2/Xn) Certification and badging guidelines and parts of end-to-end, inter-operability and conformance testing For more details on the new specifications, please check this O-RAN blog post. To download
Grand Prize Winner Announced in $5M IBM Watson AI XPRIZE Competition23.6.2021 19:30:00 CEST | Press release
XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, and IBM Watson, IBM’s AI technology for business, today announced the Grand Prize Winner in the $5M IBM Watson AI XPRIZE Challenge. First launched in 2016, the five-year global competition looked to accelerate adoption of artificial intelligence (AI) technologies and spark creative, innovative and audacious demonstrations of the technology that are truly scalable to solve societal grand challenges. Winning first place honors isZzapp Malaria, in second place is Aifred Health, followed by Marinus Analytics. These finalists were selected out of a pool of 10 semifinalists following presentations of their solutions to a panel of judges during an event held at TED headquarters in New York City last year. A $3 million grand prize, $1 million second place prize, and $500k third place prize will be awarded to the teams. In total, over 150 teams throughout the world joined the compe
New Lattice CertusPro-NX General Purpose FPGAs Deliver Advanced System Bandwidth and Memory Capabilities to Edge Applications23.6.2021 18:00:00 CEST | Press release
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the Lattice CertusPro™-NX general purpose FPGA family. As the fourth device family based on the Lattice Nexus™ platform to be launched in just 18 months, CertusPro-NX continues Lattice’s commitment to FPGA innovation with leadership power efficiency, the highest bandwidth in the smallest form factor in comparison to similar devices, and as the only FPGAs in their class with support for LPDDR4 external memory. With advanced performance capabilities and the highest logic density currently available on a Nexus-based device, CertusPro-NX FPGAs are designed to accelerate application development for the Communications, Compute, Industrial, Automotive, and Consumer markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005270/en/ The Lattice CertusPro-NX general purpose FPGA (Graphic: Business Wire) “Many Edge devices require
Echodyne Expands Market for Leading CUAS Radar, EchoGuard23.6.2021 18:00:00 CEST | Press release
Echodyne, the radar platform company, announced today substantial enhancements to its industry-leading radars, adding a new radar for international markets, a new product for special operations-type applications, a ruggedized radome, and continuing improvements in software and performance. Together, these product developments represent significant advancements to its breakthrough radar technology, MESA®. With customers in defense, national security, and critical infrastructure protection, Echodyne radars have become a core component for counter-UAS, border security, and base and perimeter 3D surveillance solutions. The products and improvements include: EchoGuard International. The new EchoGuard radar has RoHS3 construction and is compliant with CE Radio Equipment Directive (RED) compliance for EU customers, per Type Examination Certificate per 2014/53/EU Radio Equipment directive. EchoGuard spectrum expansion. Many jurisdictions allow for RadioLocation use at 24.05-24.25 GHz, and Echo
Walton Enters the Single-Family Build-to-Rent Market Using its 81,000 Acre Land Portfolio Throughout the U.S.23.6.2021 15:18:00 CEST | Press release
Walton Global Holdings has launched a build-to-rent (BTR) line of business that will leverage its more than 81,000 acres of land assets throughout the U.S. to create near-term opportunities for single-family home rental developments. Walton is a global real estate investment and land asset management company with US$3.4 billion under management making the company one of the largest pure-play residential landowners in North America. The launch of Walton’s BTR business provides the company with an immediate competitive advantage during a time when established land parcels are hard to come by for many organizations in this market. Walton’s core products have been pre-development land and land development for more than 42 years. Through its core business, Walton specializes in land acquisition to zoning and entitlements partnering with top national homebuilders throughout the U.S. Walton has already identified 17 near-term opportunities and is in advanced negotiations with a select group o
A European Leader in Retail for Automotive Launches Its Data Exchange Platform Powered by Dawex23.6.2021 15:00:00 CEST | Press release
Dawex, the leading data exchange and data marketplace technology company, today announced a European leader in retail for automotive has chosen Dawex technology to deploy its Data Exchange Platform to distribute, exchange and commercialize data products securely, in compliance with regulations. Relying on Dawex technology, the Data Exchange facilitates access to data products, accelerates data circulation and monetization, and orchestrates a data ecosystem. This data hub enables the entire sector to propose new services, improve productivity and efficiency, mitigate risk, and generate new revenue streams. Our customer’s Data Marketplace empowers participating organizations to build strong data partnerships where data providers and data acquirers benefit from the appropriate governance models to ensure participants remain in full control over the data they share, with whom they share it with, and for which usage. Dawex Data Exchange technology brings the technical, contractual, financia
IDEMIA Brings Boarding Security to Los Angeles International Airport (LAX)23.6.2021 15:00:00 CEST | Press release
IDEMIA is facilitating a facial recognition system to help U.S. Customs and Border Protection (CBP) increase air passengers’ security and border control at Los Angeles International Airport (LAX), one of the busiest airports in the world. The technology has been deployed in LAX’s new West Gates at Tom Bradley International Terminal and is a one-stop safety solution for passengers, airlines, and airports alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005420/en/ (Photo: Business Wire) The deployment is part of a contract awarded by Los Angeles World Airports (LAWA) to EASIER, a leader in e-gate technology. In alignment with protection measures defined by the U.S. Congress, passengers will now get to experience a faster, more accurate, and touchless boarding experience. LAX is just one of multiple airports where IDEMIA’s facial recognition technology is deployed in conjunction with CBP and an example of the long-te